Section of Heart Failure/Transplant/MCS and Pulmonary Hypertension, Cardiovascular Institute, Allegheny Health Network, Temple University School of Medicine, 320 East North Avenue, 16th Floor ST, Pittsburgh, PA 15212, USA.
Department of Cardiothoracic Surgery, Cardiovascular Institute, Allegheny Health Network, 320 East North Avenue, Pittsburgh, PA 15212, USA.
Crit Care Clin. 2018 Jul;34(3):479-492. doi: 10.1016/j.ccc.2018.03.010.
The clinical use of left ventricular assist devices (LVADs) in the growing epidemic of heart failure has improved quality of life and long-term survival for this otherwise devastating disease. The current generation of commercially available devices offers a smaller profile that simplifies surgical implantation, a design that optimizes blood flow characteristics, with less adverse events and improved durability than their predecessors. Despite this, the risk for adverse events remains significant, as do burdens for patients and their caregivers. Appropriate patient selection remains key to optimal LVAD outcomes.
在心力衰竭日益流行的情况下,左心室辅助装置(LVAD)的临床应用改善了生活质量和长期生存率,使这种破坏性极大的疾病得到缓解。目前市面上的新一代设备体积更小,简化了手术植入,设计优化了血流特性,与前代产品相比,不良事件更少,耐用性更高。尽管如此,不良事件的风险仍然很大,患者及其护理人员的负担也很重。合适的患者选择仍然是 LVAD 治疗效果最优化的关键。